| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/18/2001 | US6331175 Method and kit for imaging and treating organs and tissues |
| 12/15/2001 | CA2311708A1 Method of treating depression using l-threo-methylphenidate |
| 12/13/2001 | WO2001094952A2 Methods and compositions for modulating oxidized ldl transport |
| 12/13/2001 | WO2001094951A2 Inhibitors of c-reactive protein induced inflammation |
| 12/13/2001 | WO2001094645A1 Two-hybrid assay that detects hiv-1 reverse transcriptase dimerization |
| 12/13/2001 | WO2001094636A2 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 12/13/2001 | WO2001094627A2 Assay techniques based on growth stage dependent expression in c. elegans |
| 12/13/2001 | WO2001094621A1 Screening method for modulators of suv39h2-methyltransferase |
| 12/13/2001 | WO2001094620A1 Screening-method for modulators of methyltransferase-dependent chromosome stability |
| 12/13/2001 | WO2001094616A1 Protein markers for pharmaceuticals and related toxicity |
| 12/13/2001 | WO2001094613A2 Methods and compounds for influencing beta3 integrin-dependent intracellular processes |
| 12/13/2001 | WO2001094587A2 Extracellular messengers |
| 12/13/2001 | WO2001094581A1 Tumour suppressor and uses thereof |
| 12/13/2001 | WO2001094547A2 Molecular delivery vehicle for delivery of selected compounds to targets |
| 12/13/2001 | WO2001094420A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | WO2001094414A2 THE HUMAN VOLTAGE GATED SODIUM CHANNEL β-1A SUBUNIT AND METHODS OF USE |
| 12/13/2001 | WO2001094391A2 Intracellular signaling proteins |
| 12/13/2001 | WO2001094380A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 12/13/2001 | WO2001094300A1 Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament |
| 12/13/2001 | WO2001094295A1 Substituted stilbenes as glucose uptake enhancers |
| 12/13/2001 | WO2001094293A2 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | WO2001093913A2 T cell receptor fusions and conjugates and methods of use thereof |
| 12/13/2001 | WO2001093911A2 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | WO2001093909A2 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
| 12/13/2001 | WO2001093901A1 Combined preparation for the treatment of neoplasic diseases |
| 12/13/2001 | WO2001093900A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 12/13/2001 | WO2001093892A1 Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury |
| 12/13/2001 | WO2001093881A1 Immunological substance containing enteroabsorbable anti-inflammatory factor and application thereof |
| 12/13/2001 | WO2001093865A2 Medicaments for treating dementia |
| 12/13/2001 | WO2001093859A1 Stable pharmaceutical product and formulation |
| 12/13/2001 | WO2001093857A1 Composition for pain mediation and apparatus and method of use thereof |
| 12/13/2001 | WO2001093852A2 Method of treating pain using nalbuphine and opioid antagonists |
| 12/13/2001 | WO2001093845A2 Carboxyalkylether-acat inhibitor combinations |
| 12/13/2001 | WO2001093830A1 Method for obtaining aqueous formulations of oxidation-sensitive active principles |
| 12/13/2001 | WO2001093828A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | WO2001093806A2 HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS |
| 12/13/2001 | WO2001093669A2 Compound screens relating to insulin deficiency or insulin resistance |
| 12/13/2001 | WO2001085145A8 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 12/13/2001 | WO2001072772A3 Calcium binding regulatory subunit |
| 12/13/2001 | WO2001068675A3 Treatment of rosacea |
| 12/13/2001 | WO2001055103A3 Chimeric neuropeptide y receptors |
| 12/13/2001 | WO2001047508A3 Combination of trimebutine with an opioid analgesic |
| 12/13/2001 | WO2001045668A3 Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| 12/13/2001 | WO2001044445A3 Human lyases and associated proteins |
| 12/13/2001 | WO2001042784A3 Methods for screening compounds active on neurons |
| 12/13/2001 | WO2001041701A3 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 12/13/2001 | WO2001041550A3 Topical anesthetic formulation |
| 12/13/2001 | WO2001035929A3 Biodegradable polymer composition |
| 12/13/2001 | WO2001035899A3 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 12/13/2001 | WO2001030987A3 Tankyrase h, compositions involved in the cell cycle and methods of use |
| 12/13/2001 | WO2001021008A3 Method for increasing pet activity |
| 12/13/2001 | WO2001020026A3 POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |
| 12/13/2001 | WO2001019399A3 Method of potentiating chemotherapy and treating solid tumors |
| 12/13/2001 | WO2001012192A3 Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil |
| 12/13/2001 | WO2000069390A3 Compositions for improving bioavailability of orally administered drugs |
| 12/13/2001 | WO2000044888A3 Dimethylarginine dimethylaminohydrolases |
| 12/13/2001 | WO2000033857A9 Cancer treatment composition and method using natural plant essential oils |
| 12/13/2001 | WO2000029008A9 Hiv-specific t-cell induction |
| 12/13/2001 | WO2000015845A9 T-type calcium channel |
| 12/13/2001 | WO2000014115A9 Mc4-r as target for the identification of compounds used to treat drug addiction |
| 12/13/2001 | US20010051799 Tissue volume reduction |
| 12/13/2001 | US20010051660 Method for reducing oxalate |
| 12/13/2001 | US20010051656 Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction |
| 12/13/2001 | US20010051646 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 12/13/2001 | US20010051641 A medicine for preventive/treatment of disease caused by mitochondrial membrane depolarization because of elevation of intracellular calcium ion concentration; benzodiazepine receptor antagonist, e.g.,nefiracetam; antiischemic agents |
| 12/13/2001 | US20010051636 Combination treatment for inhibiting bone loss |
| 12/13/2001 | US20010051635 Inhibits the cyclin-dependent kinase subunit of P-TEFb (positive transcription elongation factor b) required for HIV propagation and replication in human cells; low dosages; side effects reduction; AIDS |
| 12/13/2001 | US20010051624 Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| 12/13/2001 | US20010051602 Alzheimer's disease; adjust apolipoprotein concentration |
| 12/13/2001 | US20010051361 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 12/13/2001 | US20010051191 Bioflavonoid (quercetin) mixed with protelytic digestive enzyme protease (bromelin and papain), also containing cranberry; for treatment of urinary tract infections |
| 12/13/2001 | US20010051170 Use of compounds which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter |
| 12/13/2001 | US20010051155 Using immunoglobulin binding epitopes |
| 12/13/2001 | US20010051150 Microencapsulated or enteric coated; therapy for kidney diseases |
| 12/13/2001 | US20010051134 Effervescent vitaceutical compositions and related methods |
| 12/13/2001 | EP1143806A3 Method for increasing pet activity |
| 12/13/2001 | DE10027968A1 Adjuvant therapy of dementia using alpha-lipoic acid or derivative, is effective in combination with antidementia or neurotransmission improving agents in improving cognitive function in e.g. Alzheimer's disease patients |
| 12/13/2001 | DE10027170A1 Humanes PEM als Target für die Fertilitätskontrolle Human PEM as a target for fertility control |
| 12/13/2001 | DE10026833A1 Verfahren zur Identifizierung von Verbindungen zur Modulierung der Aktivität eines Tumorsuppressorgens A method for identifying compounds for modulating the activity of a tumor suppressor |
| 12/13/2001 | CA2810249A1 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2413906A1 Carboxyalkylether-acat inhibitor combinations |
| 12/13/2001 | CA2412436A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2412386A1 Two-hybrid assay that detects hiv-1 reverse transcriptase dimerization |
| 12/13/2001 | CA2411730A1 Tumour suppressor and uses thereof |
| 12/13/2001 | CA2411609A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 12/13/2001 | CA2411564A1 Method of treating pain using nalbuphine and opioid antagonists |
| 12/13/2001 | CA2411536A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | CA2411473A1 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 12/13/2001 | CA2411470A1 T cell receptor fusions and conjugates and methods of use thereof |
| 12/13/2001 | CA2411396A1 Hmg coa reductase inhibitors for promoting angiogenesis |
| 12/13/2001 | CA2411340A1 Substituted stilbenes as glucose uptake enhancers |
| 12/13/2001 | CA2411285A1 Combined preparation for the treatment of neoplasic diseases |
| 12/13/2001 | CA2411139A1 Inhibitors of c-reactive protein induced inflammation |
| 12/13/2001 | CA2411069A1 The human voltage gated sodium channel .beta.-1a subunit and methods of use |
| 12/13/2001 | CA2411062A1 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | CA2410458A1 Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury |
| 12/13/2001 | CA2410158A1 Protein markers for pharmaceuticals and related toxicity |
| 12/13/2001 | CA2409392A1 Intracellular signaling proteins |
| 12/13/2001 | CA2409342A1 Extracellular messengers |
| 12/13/2001 | CA2409268A1 Macromolecular drug complexes and compositions containing the same |